Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortive
FTV
|
+$1.27B |
| 2 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$706M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$439M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$413M |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$272M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Weyerhaeuser
WY
|
+$431M |
| 2 |
Walt Disney
DIS
|
+$223M |
| 3 |
VXX
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
|
+$213M |
| 4 |
Halliburton
HAL
|
+$211M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$204M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 8.34% |
| 2 | Financials | 5.75% |
| 3 | Healthcare | 5.71% |
| 4 | Consumer Discretionary | 5.08% |
| 5 | Industrials | 3.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SUP
4201
DELISTED
Superior Industries International
SUP
| $505K | ﹤0.01% |
29,675
+7,436
| +33% | +$143K |
|
|
PRMW
4202
DELISTED
Primo Water Corporation
PRMW
| $505K | ﹤0.01% |
31,263
-1,276
| -4% | -$20.2K |
|
|
CBIO
4203
CALL
Crescent Biopharma
CBIO
$610M
| $504K | ﹤0.01% |
350
+200
| +133% | +$302K |
|
|
CBIO
4204
PUT
Crescent Biopharma
CBIO
$610M
| $504K | ﹤0.01% |
350
| – | – |
|
4205
PUT
Crane NXT
CXT
$2.96B
| $502K | ﹤0.01% |
14,683
-288
| -2% | -$8.95K |
|
|
DENN
4206
DELISTED
Denny's
DENN
| $502K | ﹤0.01% |
34,133
-31,061
| -48% | -$469K |
|
|
RARX
4207
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $502K | ﹤0.01% |
27,742
+22,706
| +451% | +$269K |
|
|
PHH
4208
DELISTED
PHH Corporation
PHH
| $502K | ﹤0.01% |
45,720
-216,742
| -83% | -$2.36M |
|
|
ITCI
4209
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $501K | ﹤0.01% |
23,100
| – | – |
|
4210
Harmonic Inc
HLIT
$1.42B
| $500K | ﹤0.01% |
91,114
+56,386
| +162% | +$282K |
|
4211
PUT
JB Hunt Transport Services
JBHT
$25.9B
| $500K | ﹤0.01% |
4,200
+4,000
| +2,000% | +$487K |
|
4212
CALL
Direxion Daily S&P 500 Bull 3x ETF
SPXL
$7.41B
| $500K | ﹤0.01% |
9,200
+9,000
| +4,500% | +$459K |
|
4213
CALL
Penske Automotive Group
PAG
$14.3B
| $498K | ﹤0.01% |
10,500
-2,700
| -20% | -$137K |
|
|
INFN
4214
CALL
DELISTED
Infinera Corporation Common Stock
INFN
| $498K | ﹤0.01% |
68,200
-23,300
| -25% | -$198K |
|
|
SCG
4215
PUT
DELISTED
Scana
SCG
| $498K | ﹤0.01% |
12,800
-43,200
| -77% | -$1.66M |
|
|
UFS
4216
CALL
DELISTED
DOMTAR CORPORATION (New)
UFS
| $496K | ﹤0.01% |
9,500
+8,900
| +1,483% | +$448K |
|
4217
CALL
Realty Income
O
$59.6B
| $495K | ﹤0.01% |
8,978
+2,167
| +32% | +$119K |
|
|
PR
4218
Permian Resources
PR
$17.7B
| $495K | ﹤0.01% |
22,628
+14,161
| +167% | +$266K |
|
4219
PUT
Exelon
EXC
$47B
| $493K | ﹤0.01% |
15,843
-2,663
| -14% | -$81.9K |
|
4220
Acushnet Holdings
GOLF
$5.2B
| $493K | ﹤0.01% |
17,960
+14,317
| +393% | +$372K |
|
|
HAYN
4221
DELISTED
Haynes International, Inc.
HAYN
| $493K | ﹤0.01% |
13,892
+9,319
| +204% | +$355K |
|
|
SVU
4222
PUT
DELISTED
SUPERVALU Inc.
SVU
| $492K | ﹤0.01% |
15,268
-32,400
| -68% | -$947K |
|
|
BHVN
4223
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $492K | ﹤0.01% |
13,107
+1,661
| +15% | +$61.1K |
|
|
ASRT
4224
DELISTED
Assertio
ASRT
| $491K | ﹤0.01% |
1,391
-215
| -13% | -$93.9K |
|
4225
Stoneridge
SRI
$197M
| $491K | ﹤0.01% |
16,511
+3,877
| +31% | +$123K |
|
Similar funds
Barclays's Q3 2018 Portfolio in Review
As of Q3 2018, Barclays held 7,740 positions worth $144B, up 24% from $116B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Barclays deployed $22.2B of net new capital in Q3 2018, opening 680 new positions and adding to 3,884 existing holdings. Its largest new stake was iPath Series B S&P GSCI Crude Oil ETN: 5,000,000 shares worth $75.7M.
By sector, the portfolio is most concentrated in Technology at 8.3% of assets, up from 7.5% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Weyerhaeuser, an estimated $431M trimmed.
- Barclays's largest Q3 2018 buy was iPath Series B S&P GSCI Crude Oil ETN: 5,000,000 shares worth $75.7M.
- Barclays added most to Fortive in Q3 2018, an estimated $1.27B increase.
- Barclays's biggest Q3 2018 reduction was Weyerhaeuser, cutting an estimated $431M.
- Barclays fully exited Validus Hold Ltd in Q3 2018, selling an estimated $71M.
- Barclays's ten largest holdings make up 31% of its $144B portfolio in Q3 2018.
- Barclays opened 680 new positions and closed 408 in Q3 2018.
- Barclays's portfolio value rose 24% quarter-over-quarter to $144B.
Based on Barclays's 13F filing for Q3 2018, filed 14 Nov 2018.